A Phase 1/2 interventional study of Azacitidine and Pembrolizumab in Solid Tumors, Advanced Malignancies and Metastatic Cancer, sponsored by Incyte Corporation. Terminated at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-21.
Sponsored by Incyte Corporation · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Neoplasm Metastasis by Incyte Corporation — none open to participants now, none under way, none of them phase 3. Neoplasm Metastasis · Incyte Corporation.
Among the 19 studies in Neoplasm Metastasis by Incyte Corporation, this one is the 10th largest by enrollment, is one of 3 that started in 2017, is one of 7 in phase 1/2, and was the 8th registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →None of the 19 studies in Neoplasm Metastasis by Incyte Corporation is open now. The open studies under Neoplasm Metastasis, anywhere →
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 11 · Phase 3 1
First in 2010; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 70 across the 19 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Neoplasm Metastasis by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination. Treatment Group A will evaluate the DNA methyltransferase inhibitor azacitidine in combination with the programmed death receptor-1 (PD-1) inhibitor pembrolizumab and the indoleamine 2,3-dioxygenase (IDO-1) inhibitor epacadostat; Treatment Group B will evaluate the bromodomain and extra-terminal (BET) inhibitor INCB057643 with pembrolizumab and epacadostat; and Treatment Group C will evaluate the lysine-specific demethylase 1A (LSD1) inhibitor INCB059872 with pembrolizumab and epacadostat. The study will be divided into 2 parts (Part 1 and 2). Part 1 is a dose-escalation assessment to evaluate the safety and tolerability of the combination therapies. Once the recommended doses have been determined, subjects with previously treated NSCLC, microsatellite-stable colorectal cancer (CRC), head and neck squamous cell carcinoma, urothelial carcinoma, and melanoma will be enrolled into expansion cohorts in Part 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 2:
*Note: Subjects must have failed available therapies that are known to confer clinical benefit as indicated below, unless they are ineligible, intolerant, or refused standard treatment.
Subjects with histologically or cytologically confirmed NSCLC:
Subjects with recurrent (unresectable) or metastatic CRC:
Subjects with HNSCC:
Subjects with melanoma:
Subjects with urothelial carcinoma:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
Drug: Azacitidine · Drug: Pembrolizumab · Drug: Epacadostat
Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
Drug: INCB057643 · Drug: Pembrolizumab · Drug: Epacadostat
Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
Drug: Pembrolizumab · Drug: Epacadostat · Drug: INCB059872
Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.
Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.
Epacadostat tablets will be administered orally twice daily.
INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.
Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.
INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
Part 1 and 2 : Number of Participants With Treatment Emergent Adverse Events
A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug. A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).
Time frame: Baseline through 42-49 days after end of treatment, estimated up to 27 months (24 months with 100 day FU period).
Part 1 and 2: Objective Response Rate Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. A participant was considered as an objective responder if the participant had a best overall response of CR or PR.
Time frame: Every 9 weeks for the duration of study participation; estimated minimum of 6 months.
Parts 1 and 2: Percentage of Responders Determined by Immunohistochemistry
Responder is defined as an increase in the number of tumor-infiltrating lymphocytes or the ratio of CD8+ lymphocytes to T regulatory cells infiltrating tumor post-treatment versus pretreatment with pembrolizumab and epacadostat in combination with azacitidine.
Time frame: Baseline to Week 5/6 or week 8/9
Parts 1 and 2: Progression-free Survival Based on RECIST v1.1.
Defined as the time from date of first dose of study drug until the earliest date of disease progression per RECIST v1.1, or death due to any cause, if occurring sooner than progression.
Time frame: Every 9 weeks from date of randomization until the date of first documented progression or date of death from any cause whichever came first, assessed up to 24 months
Parts 1 and 2: Duration of Response Based on RECIST v1.1
Defined as the time from earliest date of disease response until the earliest date of disease progression per RECIST v1.1, or death due to any cause, if occurring sooner than progression.
Time frame: Every 9 weeks from date of randomization until the date of first documented progression or date of death from any cause whichever came first, assessed up to 24 months
The study was conducted at 8 study sites in United States, 2 sites in UK and 1 site in Spain.
| Milestone | Treatment Group A :100mg of INCB24360 | Treatment Group A :300mg of INCB24360 | Treatment Group B :INCB057643+Pembrolizumab+Epacadostat | Treatment Group C :INCB059872+Pembrolizumab+Epacadostat |
|---|---|---|---|---|
| Started | 62 | 8 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 62 | 8 | 0 | 0 |
| Withdrew: Death | 33 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 11 | 3 | 0 | 0 |
| Withdrew: Progressive disease | 9 | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 4 | 0 | 0 | 0 |
| Withdrew: Other unspecified | 2 | 0 | 0 | 0 |
A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug. A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).
| Participants | Treatment Group A :100mg of INCB24360 | Treatment Group A :300mg of INCB24360 | Treatment Group B :INCB057643+Pembrolizumab+Epacadostat | Treatment Group C :INCB059872+Pembrolizumab+Epacadostat |
|---|---|---|---|---|
| Part 1 and 2 : Number of Participants With Treatment Emergent Adverse Events | 62 | 8 | — | — |
ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. A participant was considered as an objective responder if the participant had a best overall response of CR or PR.
| Participants | Treatment Group A :100mg of INCB24360 | Treatment Group A :300mg of INCB24360 | Treatment Group B :INCB057643+Pembrolizumab+Epacadostat | Treatment Group C :INCB059872+Pembrolizumab+Epacadostat |
|---|---|---|---|---|
| Part 1 and 2: Objective Response Rate Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | 3 | 1 | 0 | 0 |
Responder is defined as an increase in the number of tumor-infiltrating lymphocytes or the ratio of CD8+ lymphocytes to T regulatory cells infiltrating tumor post-treatment versus pretreatment with pembrolizumab and epacadostat in combination with azacitidine.
| Participants | Treatment Group A :100 or 300mg of INCB24360 | Treatment Group B :INCB057643+Pembrolizumab+Epacadostat | Treatment Group C :INCB059872+Pembrolizumab+Epacadostat |
|---|---|---|---|
| Intratumoral CD8+ T cells | 14 | — | — |
| CD8+:FoxP3+ ratios | 10 | — | — |
Defined as the time from date of first dose of study drug until the earliest date of disease progression per RECIST v1.1, or death due to any cause, if occurring sooner than progression.
| Months | Treatment Group A :100mg of INCB24360 | Treatment Group A :300mg of INCB24360 | Treatment Group B :INCB057643+Pembrolizumab+Epacadostat | Treatment Group C :INCB059872+Pembrolizumab+Epacadostat |
|---|---|---|---|---|
| Parts 1 and 2: Progression-free Survival Based on RECIST v1.1. | 2.07 (1.97 to 2.17) | 2.64 (1.31 to 6.11) | — | — |
Defined as the time from earliest date of disease response until the earliest date of disease progression per RECIST v1.1, or death due to any cause, if occurring sooner than progression.
| Months | Treatment Group A :100mg of INCB24360 | Treatment Group A :300mg of INCB24360 | Treatment Group B :INCB057643+Pembrolizumab+Epacadostat | Treatment Group C :INCB059872+Pembrolizumab+Epacadostat |
|---|---|---|---|---|
| Parts 1 and 2: Duration of Response Based on RECIST v1.1 | 2.63 (2.20 to 21.85) | 1.22 (NA to NA) | — | — |
Collected over Baseline through 42-49 days after end of treatment, estimated up to 27 months (24 months with 100 day FU period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Group A :100mg of INCB24360 | 41/62 (66.1%) | 28/62 (45.2%) | 59/62 (95.2%) |
| Treatment Group A :300mg of INCB24360 | 4/8 (50%) | 3/8 (37.5%) | 8/8 (100%) |
| Event | Treatment Group A :100mg of INCB24360 | Treatment Group A :300mg of INCB24360 |
|---|---|---|
| Disease ProgressionGeneral disorders | 8/62 | 0/8 |
| LeukocytosisBlood and lymphatic system disorders | 0/62 | 1/8 |
| Sinua tachycardiaCardiac disorders | 0/62 | 1/8 |
| Abdominal PainGastrointestinal disorders | 2/62 | 1/8 |
| NauseaGastrointestinal disorders | 4/62 | 1/8 |
| VomitingGastrointestinal disorders | 2/62 | 1/8 |
| AstheniaGeneral disorders | 0/62 | 1/8 |
| Non-cardiac Chest PainGeneral disorders | 0/62 | 1/8 |
| InfectionInfections and infestations | 0/62 | 1/8 |
| Head InjuryInjury, poisoning and procedural complications | 0/62 | 1/8 |
| Event | Treatment Group A :100mg of INCB24360 | Treatment Group A :300mg of INCB24360 |
|---|---|---|
| FatigueGeneral disorders | 28/62 | 6/8 |
| Decreased appetiteMetabolism and nutrition disorders | 12/62 | 5/8 |
| NauseaGastrointestinal disorders | 34/62 | 3/8 |
| HeadacheNervous system disorders | 4/62 | 4/8 |
| ConstipationGastrointestinal disorders | 16/62 | 3/8 |
| Aspartate aminotransferase increasedInvestigations | 5/62 | 3/8 |
| DiarrhoeaGastrointestinal disorders | 12/62 | 3/8 |
| VomitingGastrointestinal disorders | 21/62 | 2/8 |
| AnaemiaBlood and lymphatic system disorders | 11/62 | 2/8 |
| Abdominal DistensionGastrointestinal disorders | 2/62 | 2/8 |
No patients enrolled in Treatment Group B and C.
| Age, Continuous(years) | Treatment Group A :100mg of INCB24360 | Treatment Group A :300mg of INCB24360 | Treatment Group B :INCB057643+Pembrolizumab+Epacadostat | Treatment Group C :INCB059872+Pembrolizumab+Epacadostat | Total |
|---|---|---|---|---|---|
| Mean | 57.0 ± 11.92 | 53.0 ± 11.31 | — | — | 56.5 ± 11.84 |
| Sex: Female, Male(Participants) | Treatment Group A :100mg of INCB24360 | Treatment Group A :300mg of INCB24360 | Treatment Group B :INCB057643+Pembrolizumab+Epacadostat | Treatment Group C :INCB059872+Pembrolizumab+Epacadostat | Total |
|---|---|---|---|---|---|
| Female | 19 | 4 | — | — | 23 |
| Male | 43 | 4 | — | — | 47 |
| Race/Ethnicity, Customized(Participants) | Treatment Group A :100mg of INCB24360 | Treatment Group A :300mg of INCB24360 | Treatment Group B :INCB057643+Pembrolizumab+Epacadostat | Treatment Group C :INCB059872+Pembrolizumab+Epacadostat | Total |
|---|---|---|---|---|---|
| White/Caucasian | 56 | 5 | — | — | 61 |
| Black/African-American | 3 | 0 | — | — | 3 |
| Asian | 2 | 0 | — | — | 2 |
| American-Indian/Alaska Native | 0 | 0 | — | — | 0 |
| Native Hawaiian/Pacific Islander | 0 | 0 | — | — | 0 |
| Other | 1 | 3 | — | — | 4 |
| Race/Ethnicity, Customized(Participants) | Treatment Group A :100mg of INCB24360 | Treatment Group A :300mg of INCB24360 | Treatment Group B :INCB057643+Pembrolizumab+Epacadostat | Treatment Group C :INCB059872+Pembrolizumab+Epacadostat | Total |
|---|---|---|---|---|---|
| Hispanic or Latino — Hispanic or Latino | 4 | 2 | 0 | 0 | 6 |
| Hispanic or Latino — Not Hispanic or Latino | 54 | 6 | 0 | 0 | 60 |
| Hispanic or Latino — Unknown | 4 | 0 | 0 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Feb 2017 to primary completion in Feb 2019, 23 months.
Results were first posted in Mar 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azacitidine · INCB057643 · INCB059872